# Retrospective Survey of Re-treatment With Bortezomib

> **NCT01524445** · — · COMPLETED · sponsor: **Janssen Pharmaceutica N.V., Belgium** · enrollment: 35 (actual)

## Conditions studied

- Hematological Cancer
- Multiple Myeloma

## Interventions

- **OTHER:** bortezomib retreatment due to relapse

## Key facts

- **NCT ID:** NCT01524445
- **Lead sponsor:** Janssen Pharmaceutica N.V., Belgium
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** —
- **Final completion:** 2011-10
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2012-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01524445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01524445, "Retrospective Survey of Re-treatment With Bortezomib". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01524445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*